CCMB to assess Ayurveda formulations' efficacy against coronavirus

Topics Ayurveda | Coronavirus | CSIR

Ayurveda formulations would be

tested on lab-grown strains of coronavirus by the CSIR-Centre for Cellular and Molecular Biology (CCMB) here to ascertain their anti-viral efficacy in the fight against the pathogen, under a pact with Kerala-based Arya Vaidya Sala (AVS).

Standardised Ayurveda formulations provided by AVS in Kottakkal would be tested on the lab-grown coronavirus in the cell culture system, the premier research institute here said on Friday.

"If it yields tangible results, the project will lead to a major progress in pharmaceutical industry in India," CCMB Director Rakesh Mishra said.

While the country possessed a lot of ancient wisdom, it has lacked defined regulatory protocols for testing the efficacy of formulations that were based on classical texts, he said.

In the ongoing fight against the coronavirus, it has become imperative to rigorously test the different treatment possibilities before they were used by the public, he said.

"At CCMB, we have established an efficacy testing facility for drugs and devices by using the lab-grown coronavirus.This can be used for testing the antiviral efficacy of Ayurvedic formulations too," Mishra said.

The AVS was joining hands with CCMB with the clear objective of attempting to validate classical knowledge of Ayurveda with the aid of modern science, AVS Senior Scientist C T Sulaiman said.

"We are hopeful that findings of this study will yield useful therapeutic support in the current situation. The chemical evaluation of the selected formulations showed presence of potent molecules, and they will be investigated further," he said.

AVS is a 118-years old charitable institution engaged in the practice and propagation of Ayurveda. It manufactured more than 500 formulations, the release said.

The CCMB, a premier life science research institute, has been testing, sequencing and growing coronavirus strains in its labs for various study purposes.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel